Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | KLK7 | P49862 | 1/20 | 0.60 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475715 | 1.00 | PREP (0.67) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL29658848 | 1.00 | PREP (0.67) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL205223 | 1.00 | PREP (0.67) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| Hydrochloric Acid SCHEMBL32677508 | 0.99 | PREP (0.65) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL630208 | 0.96 | PREP (0.62) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL82714 | 0.96 | PREP (0.62) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL630241 | 0.96 | PREP (0.62) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL18093534 | 0.95 | PREP (0.71) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL20678314 | 0.95 | PREP (0.71) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 | |
| SCHEMBL17459415 | 0.95 | PREP (0.71) | PREPALDH1A1SMN1; SMN2CTRB1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| CN-119490446-A | Synthesis method of important intermediate (S) -2-Boc-aminomethylpyrrolidine of levo-sulpride | 苏州艾缇克药物化学有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-119423091-A | Environment-friendly pesticide based on hexazinone and preparation method thereof | 江苏禾裕泰化学有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119285609-A | Preparation method of chiral 6-methyl nicotine | 恒信永基科技(深圳)有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-114998621-B | SERS quantitative analysis method based on coffee ring concentration effect and image processing technology | 嘉兴学院 | 2024-04-16 | — | — | CN | claimed |
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-113929736-B | Gly-Pro-Arg-Pro-oxaminocarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2024-01-26 | — | — | CN | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| EP-0817795-B1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | NAEJA PHARMACEUTICAL INC (CA) | 2000-11-15 | — | — | EP | claimed |
| EP-0817795-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES INC. (CA) | 1998-01-14 | — | — | EP | claimed |
| WO-1996032408-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES, INC. (US) | 1996-10-17 | — | — | WO | claimed |
| US-5221752-A | Inhibits prolyl endopeptidase activity; active ingredient of an enzyme inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-06-22 | — | — | US | claimed |
| EP-0384341-A2 | New proline derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1990-08-29 | — | — | EP | claimed |
| EP-0322765-A2 | New thiazolidine derivatives, process for preparing same and anti-amnestic composition containing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1989-07-05 | — | — | EP | claimed |
| US-4434095-A | Cyclic analogue of naturally-occurring phagocytosis-stimulant peptide - threonyl-cyclo-[-N.sup.ε -lysyl-prolyl-arginyl] | INSTITUTE ORGANICHESKOGO SINTEZA (SU) | 1984-02-28 | — | — | US | claimed |
| US-RE30496-E | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1981-01-27 | — | — | US | claimed |
| US-4085207-A | AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) | 1978-04-18 | — | — | US | claimed |
| US-4018912-A | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-04-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | PREP 1315/4885ALDH1A1 1161/4885SMN1; SMN2 592/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | PREP 1427/4885ALDH1A1 1151/4885SMN1; SMN2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.